Handa Pharmaceuticals is pursuing a dual-engine strategy focusing on the development of high-barrier/patentable generics and 505(b)(2) new drugs. From its base in the Southern Taiwan Science Park, the company has launched several drugs in the world’s largest pharmaceutical markets, including the US and Canada, and aims to introduce one new drug to the market each year to sustain growth momentum.